Minerva Neurosciences (NERV) Short-Term Debt issuances (2014 - 2015)

Minerva Neurosciences (NERV) posted Short-Term Debt issuances of -$9.8 million for Q4 2015, down 200.0% on a QoQ basis from $9.8 million in Q2 2015.

Minerva Neurosciences (NERV) Short-Term Debt issuances (2014 - 2015) Analysis & Trends

Minerva Neurosciences' Short-Term Debt issuances history runs 2 years deep, the most recent figure standing at -$9.8 million for Q4 2015.

Quarterly Short-Term Debt issuances changed N/A year-over-year to -$9.8 million in Q4 2015, while the trailing twelve-month figure through Dec 2015 was $195656.0 (down 89.61% YoY) and the FY2015 annual result came in at $195656.0, down 89.61% from the prior year.
Short-Term Debt issuances was -$9.8 million for Q4 2015 at Minerva Neurosciences, down from $9.8 million in the prior quarter.
Across five years, Short-Term Debt issuances topped out at $9.8 million in Q2 2015 and bottomed at -$9.8 million in Q4 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Short-Term Debt issuances (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	58.20 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	-
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	-
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Minerva Neurosciences	195.10 Mn	195.10 Mn	-	-

Download Data